Mr. Daragh Connolly:

Yes, plenty. From a continuity of supply perspective, 60% of medicines on my shelf or that of Ms Horan are made, labelled or boxed in the United Kingdom. Overall, 80% of the drugs in our pharmacies are transited through the United Kingdom, so there is an extra 20% on that figure. We saw that the snowstorm at the beginning of March caused a huge disruption in the delivery of everything but unfortunately people seemed to be able to get bread more quickly than they could get medicines. The supply chain is very fragile because it is so lean. Because of the FEMPI cuts imposed on us, we cannot hold the stock. FEMPI cuts were also imposed on wholesalers who now no longer hold two weeks or a month's worth of stock, stock is now measured in days. We have considerable fear in respect of Brexit regarding the continuity of supply. There is a broader question of how it will affect the economy but specifically from a pharmacy perspective we are very worried, first about continuity of supply and second, that as the only English-speaking member of the European Union, we perceive much of our product here as being overspill from the UK market. As the only English-speaking member of the EU the cost of medicines will increase if it costs more to do business here, relabelling and repacking medicines for another jurisdiction.